Ashish Kumar Agrawal

Dr. Ashish Kumar Agrawal

Indian Institute of Technology BHU, Vārānasi, Uttar Pradesh, International
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
AAAshish Kumar Agrawal
Ashish Kumar Agrawal
FAFarrukh Aqil
Farrukh Aqil
JJJeyaprakash Jeyabalan
Jeyaprakash Jeyabalan
WSWendy A. Spencer
Wendy A. Spencer
JBJoshua Beck
Joshua Beck
RGRamesh Gupta
Ramesh Gupta

18 October 2017 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
FAFarrukh Aqil
Farrukh Aqil
RMRadha Munagala
Radha Munagala
JJJeyaprakash Jeyabalan
Jeyaprakash Jeyabalan
AAAshish Kumar Agrawal
Ashish Kumar Agrawal
RGRamesh Gupta
Ramesh Gupta

1 May 2019 in Cancer Letters
Verified
Journal Article
Closed access
Farrukh AqilFarrukh Aqil
Farrukh Aqil
RMRadha Munagala
Radha Munagala
JJJeyaprakash Jeyabalan
Jeyaprakash Jeyabalan
AAAshish Kumar Agrawal
Ashish Kumar Agrawal
AKAl-Hassan Kyakulaga
Al-Hassan Kyakulaga
RGRamesh Gupta
Ramesh Gupta

1 August 2016 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
Farrukh AqilFarrukh Aqil
Farrukh Aqil
HKHina Kausar
Hina Kausar
AAAshish Kumar Agrawal
Ashish Kumar Agrawal
JJJeyaprakash Jeyabalan
Jeyaprakash Jeyabalan
AKAl-Hassan Kyakulaga
Al-Hassan Kyakulaga
RGRamesh Gupta
Ramesh Gupta

1 May 2017 in Cancer Letters
Verified
Journal Article
Closed access
RMRadha Munagala
Radha Munagala
Farrukh AqilFarrukh Aqil
Farrukh Aqil
JJJeyaprakash Jeyabalan
Jeyaprakash Jeyabalan
AAAshish Kumar Agrawal
Ashish Kumar Agrawal
AMAshley M. Mudd
Ashley M. Mudd
RGRamesh Gupta
Ramesh Gupta

21 March 2012 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
AAAshish Kumar Agrawal
Ashish Kumar Agrawal
MDManasmita Das
Manasmita Das
SJSanyog Jain
Sanyog Jain
Introduction: In situ gel systems refer to a class of novel delivery vehicles, composed of natural, semisynthetic or synthetic polymers, which present the unique property of sol–gel conversion on receipt of biological stimulus. Areas covered: The present review summarizes the latest developments in in situ gel technology, with regard to ophthalmic drug delivery. Starting with the mechanism of ocular absorption, the review expands on the fabrication of various polymeric in situ gel systems, made up of two or more polymers presenting multi-stimuli sensitivity, coupled with other interesting features, such as bio-adhesion, enhanced penetration or sustained release. Various key issues and challenges in this area have been addressed and critically analyzed. Expert opinion: The advent of in situ gel systems has inaugurated a new transom for ‘smart’ ocular delivery. By virtue of possessing stimuli-responsive phase transition properties, these systems can easily be administered into the eye, similar to normal eye drops. Their unique gelling properties endow them with special features, such as prolonged retention at the site of administration, followed by sustained drug release. Despite the superiority of these systems as compared with conventional ophthalmic formulations, further investigations are necessary to address the toxicity issues, so as to minimize regulatory hurdles during commercialization.